Osteosarcoma (OS) is a highly aggressive pediatric cancer, characterized by frequent lung
metastasis and pathologic bone destruction. Vascular endothelial growth factor A (VEGFA) …

The emerging CRISPR/Cas9 system represents a promising platform for genome editing.
However, its low transfection efficiency is a major problem hampering the application of the …

Clustered regularly interspaced short palindromic repeats/associated protein 9
(CRISPR/Cas9) gene‐editing technology shows promise for manipulating single or multiple …

In recent years, CRISPR (clustered regularly interspaced short palindromic repeat)/Cas
(CRISPR-associated) genome editing systems have become one of the most robust …

Radiotherapy is a mainstay of glioblastoma (GBM) treatment; however, the development of
therapeutic resistance has hampered the efficacy of radiotherapy, suggesting that additional …

RISPR-Cas9 has exhibited enormous potential in gene therapy. It can perform genome
editing with single-nucleotide precision in various types of cell and tissue, providing a …

Harnessing CRISPR-Cas9 technology for cancer therapeutics has been hampered by low
editing efficiency in tumors and potential toxicity of existing delivery systems. Here, we …

The-state-of-art CRISPR/Cas9 is one of the most powerful among the approaches being
developed to rescue fundamental causes of gene-based inheritable diseases. Several …

CRISPR/Cas9 gene-editing technology shows great potential for treating a variety of
diseases, such as glioblastoma multiforme (GBM). However, CRISPR components suffer …

The CRISPR/Cas9 system is an efficient genome-editing system that has been successfully
applied in the field of gene therapy. However, clinical applications of the CRISPR/Cas9 …